- Home
- NICE vs KNSA Comparison
NICE vs KNSA Comparison
Compare NICE & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NICE | KNSA |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.9B |
| IPO Year | 1999 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NICE | KNSA |
|---|---|---|
| Price | $108.22 | $78.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $153.46 | $60.86 |
| AVG Volume (30 Days) | ★ 517.5K | 414.2K |
| Earning Date | 05-14-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | $10.14 | $37.48 |
| Revenue Next Year | $9.62 | $17.87 |
| P/E Ratio | ★ $11.21 | $289.19 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $83.10 | $33.54 |
| 52 Week High | $153.62 | $82.94 |
Technical Indicators
Market Signals| Indicator | NICE | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 59.48 | 59.00 |
| Support Level | $104.33 | $44.95 |
| Resistance Level | $109.60 | $82.25 |
| Average True Range (ATR) | 3.12 | 2.23 |
| MACD | 0.25 | -0.56 |
| Stochastic Oscillator | 85.26 | 56.73 |
Price Performance
Historical ComparisonAbout NICE NICE Ltd
Nice is an enterprise software company that serves the customer engagement and financial crime and compliance markets. Software is deployed primarily on the cloud, but also on premises. Within customer engagement, Nice's CXone is the leading CCaaS platform providing solutions such as call routing, interactive voice response, digital self-service, and workforce engagement management. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money-laundering, and compliance solutions.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.